Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies
about
Molecular Insights into γδ T Cell Costimulation by an Anti-JAML AntibodyMonoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cellsA proteomic view at T cell costimulationAdvantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation.The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?Granzyme B- and Fas ligand-mediated cytotoxic function induced by mitogenic CD28 stimulation of human memory CD4+ T cellsTGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse ModelT Cells of Infants Are Mature, but Hyporeactive Due to Limited Ca2+ Influx.Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine stormCapsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses.Monoclonal antibody-induced cytokine-release syndrome.The yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk.CD28-specific immunomodulating antibodies: what can be learned from experimental models?Targeting co-stimulatory pathways: transplantation and autoimmunity.Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?Co-stimulation Blockade Plus T-Cell Depletion in Transplant Patients: Towards a Steroid- and Calcineurin Inhibitor-Free Future?CD28 Costimulation: From Mechanism to Therapy.Aptamers for CD Antigens: From Cell Profiling to Activity Modulation.Delivering safer immunotherapies for cancer.High content cellular immune profiling reveals differences between rhesus monkeys and men.A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development.The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.Single CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells.Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity.IL-2 Inducible Kinase ITK is Critical for HIV-1 Infection of Jurkat T-cells.A non-conserved amino acid variant regulates differential signalling between human and mouse CD28.Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases
P2860
Q27666534-C7D3A4E2-2514-4D93-AE65-198AEEA03700Q30048609-6088ADA6-F520-433C-B502-065F4929C9A0Q31059128-5E57353D-41D8-4613-BC54-6C48A32CDB2EQ33573593-B44C9106-B66D-4CA3-BA4B-EED70D6F5BEEQ33586493-304D682D-E87F-4966-BEEE-A8E8A708A531Q34903504-0E91CC0D-1E15-4376-90BC-C243199C4E59Q34952232-57C4B456-21CF-4B72-8917-EAB89D4A5B07Q35912982-253C587F-BFB7-4053-8D1B-D865309A9855Q35950889-906EF447-EF13-4246-B481-A84F06D8412EQ36205480-B03DC7F2-C947-4D5F-AA62-F2475845A6B5Q36214559-3D0662A0-AB61-47B9-8B3E-EC33E31E6D67Q36621100-9C0C690C-37C4-4515-A629-9394A56D0B0DQ37209197-347C9D8C-1144-47F7-8E79-E1FBC45D35F8Q37379764-0EBD122E-74FF-4B20-B308-F62363033CFDQ37576726-FC873F22-ADCF-4567-9322-62A604124432Q37755276-E19CF4A6-CA74-4AA2-9D3E-3C847C722B76Q37973651-D86B2EEA-DC4C-4641-BBB9-AAA41EF56A21Q37999397-6E0FEB93-48DF-426D-B610-6BB8E2E4F49BQ38150101-52004643-9EA7-49A7-9D94-3F4727089291Q38698683-2CBEAE3C-903C-4BD6-85C6-7F61380DE2C9Q38804454-CCFA7A02-3B91-4D05-ACEE-FE8937B44BC3Q38837466-4E13B06D-BD6C-41A9-8EA3-A82E562486F2Q39191316-C6585824-1C84-4D9B-A904-A6E7C150C5FCQ39330984-A349A88D-7034-431B-8A33-A1796D262850Q39873561-580DA79F-496A-439B-AEEB-9571025EF189Q40703054-E6873E45-3889-4C09-BDAA-683C39FE17ACQ40748706-47F6A181-6EAC-48E3-AB59-BD64EAA44D61Q41791447-C9E7096A-D683-4D7B-BC65-BE2A92FD98D2Q41983238-CD14DB9B-37EF-4EEE-B4AB-4351281254B0Q49911885-8BBF68AF-1DD2-4829-A1A5-E43671555AA3Q55174942-17BDD7D5-F972-42F6-9960-14B81FEABBF1Q57965147-C0C152DB-7550-495C-B95F-79B45FB4E116
P2860
Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Signaling signatures and funct ...... CD28 superagonistic antibodies
@ast
Signaling signatures and funct ...... CD28 superagonistic antibodies
@en
Signaling signatures and funct ...... CD28 superagonistic antibodies
@nl
type
label
Signaling signatures and funct ...... CD28 superagonistic antibodies
@ast
Signaling signatures and funct ...... CD28 superagonistic antibodies
@en
Signaling signatures and funct ...... CD28 superagonistic antibodies
@nl
prefLabel
Signaling signatures and funct ...... CD28 superagonistic antibodies
@ast
Signaling signatures and funct ...... CD28 superagonistic antibodies
@en
Signaling signatures and funct ...... CD28 superagonistic antibodies
@nl
P2093
P2860
P1433
P1476
Signaling signatures and funct ...... CD28 superagonistic antibodies
@en
P2093
Burkhart Schraven
Camilla Merten
Linda Y Sender
Peter Reichardt
Roland Hartig
Stefanie Kliche
Zoe Waibler
P2860
P356
10.1371/JOURNAL.PONE.0001708
P407
P577
2008-01-01T00:00:00Z